Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 12, 2012 - Issue 11
Submit an article Journal homepage
106
Views
2
CrossRef citations to date
0
Altmetric
Drug Profile

Darbepoetin alfa in the treatment of anemia in cancer patients undergoing chemotherapy

Isabelle Wauters Respiratory Oncology Unit (Pulmonology) and Leuven Lung Cancer Group, University Hospital Gasthuisberg, Catholic University, Leuven, Belgium
&
Johan Vansteenkiste Respiratory Oncology Unit (Pulmonology) and Leuven Lung Cancer Group, University Hospital Gasthuisberg, Catholic University, Leuven, Belgium. [email protected]
Pages 1383-1390 | Published online: 10 Jan 2014

References

  • Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 91(12), 2214–2221 (2001).
  • Ludwig H, Van Belle S, Barrett-Lee P et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur. J. Cancer 40(15), 2293–2306 (2004).
  • Ludwig H, Aapro M, Bokemeyer C et al. Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: findings from the Anaemia Cancer Treatment (ACT) study. Eur. J. Cancer 45(9), 1603–1615 (2009).
  • Lin FK, Suggs S, Lin CH et al. Cloning and expression of the human ­erythropoietin gene. Proc. Natl Acad. Sci. USA 82(22), 7580–7584 (1985).
  • Cascinu S, Fedeli A, Del Ferro E, Luzi ­Fedeli S, Catalano G. Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo. J. Clin. Oncol. 12(5), 1058–1062 (1994).
  • Cazzola M, Messinger D, Battistel V et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin’s lymphoma: dose finding and identification of predictors of response. Blood 86(12), 4446–4453 (1995).
  • Witzig TE, Silberstein PT, Loprinzi CL et al. Phase III, randomized, double-blind study of epoetin a compared with placebo in anemic patients receiving chemotherapy. J. Clin. Oncol. 23(12), 2606–2617 (2005).
  • Elliott S, Lorenzini T, Asher S et al. Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat. Biotechnol. 21(4), 414–421 (2003).
  • Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp. Hematol. 31(4), 290–299 (2003).
  • Vansteenkiste J, Pirker R, Massuti B et al.; Aranesp 980297 Study Group. Double-blind, placebo-controlled, randomized Phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J. Natl Cancer Inst. 94(16), 1211–1220 (2002).
  • Hedenus M, Adriansson M, San Miguel J et al.; Darbepoetin alfa 20000161 Study Group. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br. J. Haematol. 122(3), 394–403 (2003).
  • Canon JL, Vansteenkiste J, Bodoky G et al. Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. J. Natl Cancer Inst. 98(4), 273–284 (2006).
  • Bastit L, Vandebroek A, Altintas S et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J. Clin. Oncol. 26(10), 1611–1618 (2008).
  • Pedrazzoli P, Farris A, Del Prete S et al. Randomized trial of intravenous iron supplementation in patients with ­chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J. Clin. Oncol. 26(10), 1619–1625 (2008).
  • Auerbach M, Silberstein PT, Webb RT et al. Darbepoetin alfa 300 or 500 µg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. Am. J. Hematol. 85(9), 655–663 (2010).
  • Varricchio CG, Sloan JA. The need for and characteristics of randomized, Phase III trials to evaluate symptom management in patients with cancer. J. Natl Cancer Inst. 94(16), 1184–1185 (2002).
  • Bohlius J, Schmidlin K, Brillant C et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 373(9674), 1532–1542 (2009).
  • Glaspy J, Crawford J, Vansteenkiste J et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br. J. Cancer 102(2), 301–315 (2010).
  • Henry DH, Dahl NV, Auerbach MA. Thrombocytosis and venous thromboembolism in cancer patients with chemotherapy induced anemia may be related to ESA induced iron restricted erythropoiesis and reversed by administration of IV iron. Am. J. Hematol. 87(3), 308–310 (2012).
  • Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B; Epoetin a Study Group. Effects of epoetin a on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J. Clin. Oncol. 19(11), 2865–2874 (2001).
  • Leyland-Jones B, Semiglazov V, Pawlicki M et al. Maintaining normal hemoglobin levels with epoetin a in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J. Clin. Oncol. 23(25), 5960–5972 (2005).
  • Untch M, von Minckwitz G, Konecny GE et al.; Arbeitsgemeinschaft Gynäkologische Onkologie PREPARE investigators. PREPARE trial: a randomized Phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin–cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer – outcome on prognosis. Ann. Oncol. 22(9), 1999–2006 (2011).
  • Smith RE, Aapro MS, Ludwig H et al. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a Phase III, multicenter, randomized, double-blind, placebo-controlled study. J. Clin. Oncol. 26(7), 1040–1050 (2008).
  • Wright JR, Ung YC, Julian JA et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J. Clin. Oncol. 25(9), 1027–1032 (2007).
  • Henke M, Laszig R, Rübe C et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362(9392), 1255–1260 (2003).
  • Overgaard J, Hoff CM, Hansen HS et al. Randomized study of the importance of Novel Erythropoiesis Stimulating Protein (Aranesp®) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC) – the Danish Head and Neck Cancer Group DAHANCA 10 randomized trial. Eur. J. Cancer 5, 6 (2007).
  • ODAC-FDA. ODAC-FDA briefing document on erythropoiesis stimulating agents (2008).
  • Hedenus M, Vansteenkiste J, Kotasek D, Austin M, Amado RG. Darbepoetin alfa for the treatment of chemotherapy-induced anemia: disease progression and survival analysis from four randomized, double-blind, placebo-controlled trials. J. Clin. Oncol. 23(28), 6941–6948 (2005).
  • Bohlius J, Langensiepen S, Schwarzer G et al. Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J. Natl Cancer Inst. 97(7), 489–498 (2005).
  • Bohlius J, Wilson J, Seidenfeld J et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J. Natl Cancer Inst. 98(10), 708–714 (2006).
  • Bohlius J, Schmidlin K, Brillant C et al. Erythropoietin or darbepoetin for patients with cancer – meta-analysis based on individual patient data. Cochrane Database Syst. Rev. 3, CD007303 (2009).
  • Ross SD, Allen IE, Henry DH, Seaman C, Sercus B, Goodnough LT. Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature. Clin. Ther. 28(6), 801–831 (2006).
  • Aapro M, Coiffier B, Dunst J, Osterborg A, Burger HU. Effect of treatment with epoetin b on short-term tumour progression and survival in anaemic patients with cancer: a meta-analysis. Br. J. Cancer 95(11), 1467–1473 (2006).
  • Ludwig H, Crawford J, Osterborg A et al. Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. J. Clin. Oncol. 27(17), 2838–2847 (2009).
  • Vansteenkiste J, Glaspy J, Henry D et al. Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses. Lung Cancer 76(3), 478–485 (2012).
  • Aapro MS, Link H. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist 13(Suppl. 30), 33–36 (2008).
  • Schrijvers D, De Samblanx H, Roila F. Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use. Ann Oncol 21(Suppl. 5), 244–247 (2010).
  • Rizzo JD, Brouwers M, Hurley P et al.; American Society of Clinical Oncology; American Society of Hematology. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J. Clin. Oncol. 28(33), 4996–5010 (2010).
  • Wauters I, Vansteenkiste J. Erythropoiesis stimulating agents in cancer patients: reflections on safety. Expert Rev. Clin. Pharmocol. 4, 467–476 (2011).
  • Vansteenkiste J, Hedenus M, Gascon P et al. Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level <10 g/dl versus > or = 10 g/dl: an exploratory analysis from a randomized, double-blind, active-controlled trial. BMC Cancer 9, 311 (2009).
  • Nitz U, Gluz O, Oberhoff C et al. Adjuvant chemotherapy with or without darbepoetin alfa in node-positive breast cancer: survival and quality-of-life analysis from the ­prospective randomized WSG ARA PLUS trial. Presented at: San Antonio Breast Cancer ­Symposium. San Antonio, TX, USA, 6–10 December 2011.
  • Delarue R, Haioun C, Coiffier B et al. Survival effect of darbepoetin alfa in patients with diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: the LNH03-6B study. J. Clin. Oncol. 29, Abstract 9048 (2011).
  • Grote T, Yeilding AL, Castillo R et al. Efficacy and safety analysis of epoetin a in patients with small-cell lung cancer: a randomized, double-blind, placebo-controlled trial. J. Clin. Oncol. 23(36), 9377–9386 (2005).
  • Aapro M, Leonard RC, Barnadas A et al. Effect of once-weekly epoetin β on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of ­Erythropoietin (BRAVE) study. J. Clin. Oncol. 26(4), 592–598 (2008).
  • Hoskin PJ, Robinson M, Slevin N, Morgan D, Harrington K, Gaffney C. Effect of epoetin a on survival and cancer treatment-related anemia and fatigue in patients receiving radical radiotherapy with curative intent for head and neck cancer. J. Clin. Oncol. 27(34), 5751–5756 (2009).
  • Machtay M, Pajak TF, Suntharalingam M et al.; Radiation Therapy Oncology Group. Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the Radiation Therapy Oncology Group (RTOG 99-03). Int. J. Radiat. Oncol. Biol. Phys. 69(4), 1008–1017 (2007).
  • Blohmer JU, Paepke S, Sehouli J et al. Randomized Phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin a in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study. J. Clin. Oncol. 29(28), 3791–3797 (2011).
  • Moebus V, Jackisch C, Lueck HJ et al. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO Phase III study. J. Clin. Oncol. 28(17), 2874–2880 (2010).
  • Pirker R, Ramlau RA, Schuette W et al. Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide. J. Clin. Oncol. 26(14), 2342–2349 (2008).
  • Hernandez E, Ganly P, Charu V et al.; ARANESP 20030232 Study Group. Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia. Curr. Med. Res. Opin. 25(9), 2109–2120 (2009).
  • Chang J, Couture F, Young S, McWatters KL, Lau CY. Weekly epoetin a maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J. Clin. Oncol. 23(12), 2597–2605 (2005).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.